Angina Pectoris Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Angina Pectoris Drugs Market is Segmented by Therapeutic Classes (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors), Anti-Platelets, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Angina Pectoris Drugs Market Size

Surgical Lasers Market Size

Angina Pectoris Drugs Market Analysis

The Global Angina Pectoris Drugs Market is expected to register a CAGR of 6.6% during the forecast period.

COVID-19 severely impacted the angina pectoris market during the early pandemic due to the lockdown restrictions, a decrease in the number of patient hospital visits, and supply chain disruption. For instance, the article titled "COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?" published in Pain Medicine, in November 2020, stated that the number of cardiovascular patients attending emergency rooms has decreased in the case of COVID-19. Patients have attributed the contradiction to a COVID-19 phobia, meaning that people with angina pectoris avoid going to emergency rooms since they were afraid of becoming infected with the virus. Such incidents negatively impacted the market's growth in the initial phase of the outbreak. However, the demand for angina pectoris drugs is likely to increase with the growing implications of heart disease among COVID-19 patients. For instance, as per a study titled "Long COVID-19 and microvascular disease-related angina" published in Sociedad Española de Cardiología, in November 2021, after meticulous evaluation and exclusion of other illnesses, the researchers found that 27% of the patients evaluated in a long COVID-19 unit had chest pain, some of which was suggestive of angina. A total of 186 patients were enrolled in the trial, 51 (27%) of whom reported ongoing chest pain after being examined in the long COVID-19 unit. Thus, such studies highlighted the need for drugs to manage angina pectoris in COVID-19 patients, ultimately boosting the demand for drugs. Therefore, the growing number of COVID-19 patients with cardiological complications is likely to boost the market's growth over the forecast period.

Furthermore, factors driving the market growth include the rising burden of lifestyle diseases, especially cardiac disorders; technological advancements towards personalized cardiovascular medicine; and the augmentation of novel drug delivery systems.

One of the major driving factors for the market growth is the surge in the patient population suffering from cardiac disorders such as coronary heart disease. For instance, as per the data published by the World Health Organization, in December 2020, ischemic heart disease was the world's leading cause of death, accounting for 16 percent of all deaths. This disease has shown the highest increase in deaths since 2000, increasing by more than 2 million to 8.9 million deaths in 2019. Stroke and chronic obstructive pulmonary disease (COPD) are the second and third largest causes of death, accounting for around 11% and 6% of all deaths, respectively. In addition, an article titled "Angina: contemporary diagnosis and management" published in PubMed Central, in February 2020, stated that Ischemic heart disease (IHD) continues to be the largest cause of death and lost life years in adults, particularly among women under the age of 55. Angina pectoris is a typical clinical manifestation of IHD and is chest discomfort caused by a heart attack. Thus, the growing number of patients suffering from IHD is likely to impel the market growth for angina pectoris drugs over the analysis period, thereby driving the market growth. However, increasing adoption of minimally invasive surgeries and side effects associated with certain drug classes are some of the factors that may hinder the market's growth in the coming years.

Angina Pectoris Drugs Industry Overview

The angina pectoris drugs market is moderately competitive with the presence of many players in the market. Some of the prominent industry players operating in total Angina Pectoris Drugs market include Amgen, Bayer AG, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc and Merck & Co., Inc. Development of advanced products for better outcomes and rigorous marketing are some of the competitive strategies adopted by market players.

Angina Pectoris Drugs Market Leaders

  1. Amgen

  2. Eli Lilly and Company

  3. Gilead Sciences

  4. GlaxoSmithKline Plc.

  5. Bayer AG

  6. *Disclaimer: Major Players sorted in no particular order
Amgen, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc., Bayer AG
Need More Details on Market Players and Competiters?
Download PDF

Angina Pectoris Drugs Market News

  • In March 2022, Zydus Lifesciences received approval from the United States Food and Drug Administration (FDA) to market its Nitroglycerin Sublingual Tablets in the strengths of 0.3 mg, 0.4mg, and 0.6mg (US RLD: Nitrostat Sublingual Tablets) for angina.
  • In October 2021, BioCardia, Inc. announced the treatment of the patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with refractory angina.

Angina Pectoris Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Deliverables and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Lifestyles Diseases
    • 4.2.2 Technological Advancements towards Personalized Cardiovascular Medicines
    • 4.2.3 Augmentation of Novel Drug Delivery Systems
  • 4.3 Market Restraints
    • 4.3.1 Increasing Adoption of Minimally Invasive Surgeries
    • 4.3.2 Side Effects Associated with Certain Drug Classes
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Therapeutic Class
    • 5.1.1 Beta Blockers
    • 5.1.2 Calcium Channel Blockers
    • 5.1.3 Nitrates
    • 5.1.4 Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
    • 5.1.5 Anti-Platelets
    • 5.1.6 Others
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen
    • 6.1.2 Bayer AG
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Gilead Sciences
    • 6.1.5 GSK Plc
    • 6.1.6 Merck & Co., Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Otsuka Pharmaceutical Co. Ltd
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sanofi
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Angina Pectoris Drugs Industry Segmentation

As per the scope of the report, Angina pectoris refers to a strangling or pressure-like pain caused by cardiac ischemia. Angina drugs are the initial treatment of angina pectoris. The antianginal drugs recommended for initial treatment are β blockers and calcium channel blockers, which reduce myocardial ischemia by heart rate reduction and vasodilatory mechanisms, respectively. Either or both of these drug classes should be prescribed, together with a short-acting nitrate for prompt alleviation of angina attacks. The Angina Pectoris Drugs Market is segmented by therapeutic class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors, Anti-Platelets, and Others) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for all the above segments.

By Therapeutic Class Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Angina Pectoris Drugs Market Research FAQs

What is the current Global Angina Pectoris Drugs Market size?

The Global Angina Pectoris Drugs Market is projected to register a CAGR of 6.6% during the forecast period (2025-2030)

Who are the key players in Global Angina Pectoris Drugs Market?

Amgen, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc. and Bayer AG are the major companies operating in the Global Angina Pectoris Drugs Market.

Which is the fastest growing region in Global Angina Pectoris Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Angina Pectoris Drugs Market?

In 2025, the North America accounts for the largest market share in Global Angina Pectoris Drugs Market.

What years does this Global Angina Pectoris Drugs Market cover?

The report covers the Global Angina Pectoris Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Angina Pectoris Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Angina Pectoris Drugs Industry Report

Statistics for the 2025 Global Angina Pectoris Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Angina Pectoris Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Global Angina Pectoris Drugs Report Snapshots

Compare market size and growth of Global Angina Pectoris Drugs Market with other markets in Healthcare Industry

Angina Pectoris Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)